SNYR enters the back half of May with a bruising quarter behind it and a fresh equity offering on the table.
Q1 results, reported on May 14, came in sharply below expectations. Revenue of $5.5 million missed the Street estimate of $9.5 million. EPS landed at -$0.23, far short of the $0.04 consensus. The stock has fallen 54% over the past month and closed Thursday at $0.29. The next day brought a -4.4% follow-on move. The April earnings release — a separate event — triggered an even more severe reaction: the stock dropped 38% in a single session and fell 50% over the subsequent five days.
The more immediate pressure on shareholders comes from the capital structure. On May 15, Synergy filed an S-1 to register the resale of up to 101.7 million shares under a new equity purchase agreement that could raise up to $36 million for the company. With shares outstanding already around 14.7 million and a stock trading near $0.29, that filing represents an enormous potential dilution. Investors absorbing a revenue miss are now also weighing the scale of that overhang.
Lending conditions tell an interesting story of their own. Borrowing costs remain extremely elevated at 113% annualised — a punishing rate for anyone holding a short position — but have eased sharply from the 313% peak reached in mid-April. Short interest spiked to nearly 1.1 million shares in late April and early May, then collapsed roughly 69% over the past week to around 331,000 shares, or about 2.9% of the float. Despite that retreat, borrow availability is still tight relative to recent norms: the 52-week high on utilisation reached 100%, and the lending pool has seen wide swings. The combination of high cost-to-borrow and falling short positions suggests some shorts have exited rather than pressed the trade — a notable development given the continued fundamental deterioration.
Analyst coverage is sparse and the data is dated. Ascendiant Capital raised its target from $5.00 to $5.50 on April 14 while maintaining a Buy rating. That target, set at 19x the current price, looks entirely disconnected from where the stock trades today and should be treated as stale in light of the Q1 miss. Roth Capital also carries a Buy with a $7.00 target from November 2025 — equally divorced from current price action. The ORTEX short score eased to 55.6 from a high of 79.0 on May 11, reflecting the reduction in short shares outstanding, though it remains elevated. The days-to-cover rank sits near the 95th percentile of all stocks — meaning even at the current lower short interest level, it would take a disproportionately long time for shorts to unwind given typical trading volume.
The biggest single holder, Chairman and CEO Jack Ross, controls nearly 30% of the company. His last recorded open-market buys were in July 2025 at prices between $3.15 and $3.90 — a cluster that now sits more than 90% above current trading levels. Those purchases were modest in dollar terms (under $5,000 per transaction) and no more recent insider activity is available, so they offer limited signal for this week's setup.
The next formal event is a Q2 earnings release scheduled for June 29. Between now and then, the trajectory of the S-1 registration — whether Synergy draws down heavily on the equity purchase facility, and at what price levels — is the single most important variable to track.
See the live data behind this article on ORTEX.
Open SNYR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
